Zimmer Biomet Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Zimmer Biomet Holdings, Inc. on December 14, 2018. The filing details the entry into a new material definitive agreement regarding corporate debt financing and the termination of a prior credit agreement.
Key Financial Metrics and Debt Structure
- New Facility: Entered into a two-year unsecured multi-draw term loan facility (2018 Term Facility) with a principal amount of $900.0 million.
- Initial Borrowing: Borrowed $675.0 million on December 14, 2018.
- Interest Rates: Floating rates based on LIBOR plus a margin of 0.875% per annum for Eurodollar-indexed loans; alternate base rate plus 0.0% for non-Eurodollar-indexed loans.
- Covenants: Requires maintaining a consolidated indebtedness to consolidated EBITDA ratio of no greater than 4.5 to 1.0.
- Debt Repayment: Proceeds were used to fully repay the $295.0 million balance of the 2014 U.S. Term Loan A and $375.0 million of the 2016 U.S. Term Loan B.
Material Changes Versus Prior Period
The Company terminated the 2014 Credit Agreement in full following the repayment of the U.S. Term Loan A. The 2018 Credit Agreement replaces the previous financing structure with a new facility administered by Bank of America, N.A., whereas the prior facility was administered by JPMorgan Chase Bank, N.A.
Outlook, Management Commentary, and Risks
- Future Borrowing: The Company intends to borrow the remaining $225.0 million available under the 2018 Credit Agreement in January 2019 to repay the remaining balance of the U.S. Term Loan B.
- Use of Proceeds: Funds are designated for general corporate purposes, transaction costs, and refinancing existing debt.
- Restrictions: If the Company does not maintain Investment Grade Standing, additional restrictions will apply, including limitations on investments and dividend payments.
- Forward-Looking Statements: The filing contains forward-looking statements regarding intended future borrowing, which are subject to risks and uncertainties that could cause actual results to differ materially.
Key Facts for Investor Verification
- Verify the execution of the full $900.0 million drawdown in January 2019 as intended.
- Monitor the Company's consolidated indebtedness to consolidated EBITDA ratio to ensure compliance with the 4.5 to 1.0 covenant.
- Confirm the Company's credit rating status to assess potential restrictions on dividends and investments.
- Review the full text of the 2018 Credit Agreement (Exhibit 10.1) for detailed affirmative and negative covenants.